Ipamorelin is a synthetic five-residue peptide that activates the ghrelin-receptor pathway and stimulates growth hormone release. Its development connects two biological settings: pituitary hormone secretion and movement of the stomach and bowel. Early experiments established a comparatively selective hormone response in animals, followed by a human exposure study showing a discrete episode of growth hormone release. The later postoperative programme supplied a more direct clinical test: a placebo-controlled bowel-resection trial found no significant improvement in its principal meal-tolerance comparison. Together, these studies explain both the interest in ipamorelin and the gap between a measurable receptor response and a useful treatment outcome.
Overview
Ipamorelin, also called NNC 26-0161, belongs to the growth hormone secretagogue family. A secretagogue prompts a cell to release a substance it already produces; here the relevant pituitary cells release growth hormone (GH). Its sequence includes nonstandard amino-acid building blocks and two D-amino acids. These structural choices distinguish it from natural ghrelin and from the related six-residue peptides GHRP-2 and GHRP-6. Raun and colleagues defined the peptide and compared its activity across cultured pituitary cells, rats and conscious pigs.
Molecular profile
Forms and derivatives
Ipamorelin acetate
An acetate salt of the ipamorelin peptide core. FDA discusses its aggregation, impurity and immunogenicity concerns; counterion composition and formulation require their own material description.
Ipamorelin with a GHRH analogue
Combining ipamorelin with another hormone-releasing molecule creates a separate intervention. The reviewed ipamorelin studies do not establish clinical outcomes for a commercial combination.
The sequence identifies the peptide core. Acetate describes a salt preparation, whose composition and formulation also matter when interpreting product identity. The clinical papers reviewed here identify their trial material as ipamorelin; they do not establish that every product carrying that name has the same purity, stability or exposure.
Uses and research areas
The original endocrine research examined GH secretion and the accompanying hormone panel. Human pharmacology then asked how circulating ipamorelin related to the GH response. These measurements helped characterize the molecule as a research tool for the hormone axis.
Ghrelin signaling also participates in gastrointestinal movement, making postoperative ileus a separate development opportunity. Ileus is the delayed return of coordinated bowel function after an operation. Rat studies examined transit, gastric emptying and stomach-muscle contraction; the subsequent clinical trial measured the time patients needed to tolerate a standardized solid meal after bowel resection. This sequence of experiments supplies substantially more context than a general claim about “recovery.” The reviewed human studies do not establish improvements in strength, body composition, sleep or healthy aging. Venkova et al., Beck et al.
Mechanism of action
Ipamorelin acts through the growth hormone secretagogue receptor pathway, now associated with the ghrelin receptor GHS-R1a. In the foundational rat pituitary experiments, GHRP-pathway antagonists inhibited its GH-releasing activity, while a GHRH-pathway antagonist had a different profile. That pharmacological comparison helped identify the signaling route. GHRH is the hypothalamic hormone that normally helps the pituitary release GH; the secretagogue pathway adds another input to the same endocrine system. Raun et al.
The animal selectivity result concerns the accompanying hormones. In conscious pigs, ipamorelin increased GH while ACTH and cortisol remained statistically comparable to the responses after GHRH. GHRP-2 and GHRP-6 increased those stress-axis hormones under the tested conditions. This is the origin of ipamorelin’s “selective” description. It defines an observed hormone panel in that model, and leaves the broader human safety question to clinical studies.
The gastrointestinal work investigated a different output of ghrelin signaling. Separate groups of surgically manipulated rats provided gastric-emptying measurements and isolated gastric-fundus tissues. Ipamorelin improved emptying and restored contraction responses to acetylcholine and electrical stimulation, supporting a role for excitatory cholinergic nerves in stomach movement. Greenwood-Van Meerveld et al.
Pharmacokinetics
Gobburu and colleagues measured ipamorelin and GH concentrations in healthy men after 15-minute intravenous infusions at five exposure levels, with eight subjects described at each level. The abstract does not resolve whether the groups contained forty distinct people. Their model estimated an ipamorelin terminal half-life of about two hours, clearance of 0.078 L/hour/kg and steady-state distribution volume of 0.22 L/kg. Exposure was dose proportional across the tested range; no precision interval for the half-life is supplied in the abstract.
Gobburu and colleagues measured circulating ipamorelin after 15-minute infusions into a vein in healthy men. The reported terminal half-life was two hours; the abstract gives no numerical uncertainty or averaging convention for that estimate. The abstract describes groups of eight men at five dose levels; it is unclear whether any men participated at more than one level. The peptide’s disappearance and the separately measured growth-hormone response describe different processes.
The GH response formed a single episode, peaking at approximately 0.67 hours. Its timing reflects secretion and clearance of GH as well as the peptide stimulus. The two-hour peptide half-life and the GH peak therefore describe different measurements. Variation between individuals was greater for the modeled hormone response than for peptide pharmacokinetics.
The rat comparison by Johansen et al. helps explain why kinetics should remain compound specific. After intravenous administration, ipamorelin cleared about five times more slowly than GHRP-6. Urinary elimination predominated for ipamorelin, whereas GHRP-6 was mainly excreted in bile. The same paper examined nasal absorption in male rats; those findings provide a formulation-development context, while human route comparisons require their own measurements.
Research findings
Bowel transit and gastric emptying after experimental surgery
The 2009 postoperative-ileus study used fasted male rats after laparotomy and intestinal manipulation, comparing ipamorelin with the carrying preparation without ipamorelin and with GHRP-6. A single ipamorelin exposure shortened time to the first bowel movement under the effective condition, while cumulative fecal output, food intake and weight gain remained unchanged over 48 hours. Repeated exposure improved those later recovery measures. The experiment thus distinguished an early transit response from the fuller recovery pattern.
The 2012 gastric study tested how quickly a meal left the stomach in rats after surgery. The investigators gave a radiolabeled test meal and measured the fraction remaining fifteen minutes later. Rats given the control liquid without ipamorelin retained 78% ± 5%, compared with 52% ± 11% under one effective ipamorelin condition and 44% ± 6% in rats that had not undergone surgery. Less meal remaining means that more had left the stomach. The tissue-contraction experiments came from a separate group of rats. Combining these observations supports a motility hypothesis without treating them as one continuous measurement in the same animals.
The clinical postoperative comparison
The multicenter, double-blind Beck trial enrolled 117 adults undergoing open or laparoscopic small- or large-bowel resection. Its safety and modified intention-to-treat populations included 114 patients. Intravenous trial treatment or placebo began postoperatively, and observation continued through discharge or seven days. The key endpoint was time from first study treatment to tolerance of a standardized solid meal.
Half the ipamorelin group could tolerate the standardized solid meal by 25.3 hours after first treatment, compared with 32.6 hours in the placebo group. Although the observed median was earlier with ipamorelin, the trial did not establish that treatment shortened this time (P = 0.15), and its secondary measures also failed to establish an advantage. Participants had different bowel operations, and the sample was small, leaving the size of any recovery benefit uncertain. FDA’s 2024 presentation retained this unsuccessful overall comparison in its effectiveness assessment.
Safety and tolerability
Ipamorelin has no FDA-approved therapeutic indication. The surgical trial reported treatment-emergent adverse events in 87.5% of the ipamorelin group and 94.8% of the placebo group, reflecting a setting in which postoperative events were common. Those aggregate percentages do not establish equivalence for each serious event. Beck et al.
FDA identifies serious events, including deaths, in intravenous gastric-motility research and notes inadequate safety information for certain other injectable routes. Its compounding safety assessment also flags aggregation, peptide-related impurities and possible immune reactions for ipamorelin acetate. An event occurring during treatment requires evaluation of the patient’s illness, comparison group and attribution; the FDA statement should not be read as a demonstrated causal death risk of a quantified magnitude.
The peptide’s ability to stimulate GH remains relevant even when another hormone response is smaller in an animal comparison. Long-term endocrine exposure, glucose regulation, uncommon adverse effects and combination-product safety were not resolved by the acute human pharmacology study or the short surgical trial.
What the research means
Ipamorelin has demonstrated pharmacological activity: the peptide reaches plasma, triggers GH secretion and changes gastrointestinal physiology in experimental models. The human bowel trial tested whether that biology translated into faster clinical recovery and did not demonstrate a significant benefit. The useful interpretation follows that sequence from receptor activity through animal physiology to the actual patient endpoint.
The published human evidence also leaves commercial combination claims outside its tested scope. Adding a GHRH analogue changes the intervention and may change endocrine exposure. A mechanistic rationale for a larger GH response would still need a trial measuring the intended benefit and harms of that particular combination.
FAQs
What does selective GH release mean for ipamorelin?
It describes the hormone panel in the foundational animal comparison. In conscious pigs, ipamorelin stimulated GH while ACTH and cortisol responses remained statistically comparable to those after GHRH. The result identifies selectivity within that model; comprehensive human safety requires clinical event and endocrine follow-up. Raun et al.
Did the bowel-recovery trial demonstrate a benefit?
After bowel resection, patients received IV ipamorelin or placebo, and investigators timed how long they took to tolerate a standardized solid meal. The median was 25.3 hours with ipamorelin and 32.6 hours with placebo, but the trial did not establish a treatment advantage; secondary measures were also inconclusive. Beck et al.
Does the two-hour half-life describe the GH pulse?
The half-life describes terminal disappearance of measured ipamorelin after intravenous infusion in healthy men. GH was a separate analyte, with its own secretion and clearance. A peptide concentration curve cannot by itself establish clinical duration or the timing of a repeated intervention. Gobburu et al.
What evidence supports ipamorelin combinations?
The studies summarized here examined ipamorelin itself. A GHRH analogue supplies another endocrine signal and changes the intervention. Its mechanism can motivate a combination experiment, while clinical benefit and safety depend on measurements of the actual combined preparation.
Comparisons and related reading
GHRP-2, GHRP-6 and hexarelin share secretagogue biology but differ in the evidence available for appetite, stress-axis hormones, cardiac physiology and repeated responsiveness. Reading those profiles alongside ipamorelin helps separate a family resemblance from an experimentally demonstrated property of one member.
References
Defines the amidated pentapeptide and compares GH release and other hormones in rat cells, rats and conscious pigs.
Human serial measurements distinguish circulating ipamorelin from the modeled GH episode.
The male-rat comparison establishes compound-specific clearance, excretion and nasal absorption.
Postoperative rat experiments distinguish first bowel movement from later food intake and fecal-output responses.
Gastric-emptying and isolated-tissue experiments used separate rat groups after surgical manipulation.
The controlled postoperative trial reports a negative overall meal-tolerance and secondary-efficacy comparison.
Alternate original full-paper URL retained from the baseline acquisition.
The clinical-effectiveness discussion retains the negative overall postoperative comparison.
The agency identifies substance- and route-specific safety concerns and gaps for compounded peptides.
Glossary
- Secretagogue
- A substance that prompts a cell to release a product it already makes.
- GHS-R1a
- The ghrelin receptor subtype associated with GH-secretagogue signaling.
- GHRH
- Growth hormone-releasing hormone, a hypothalamic input that stimulates pituitary GH secretion.
- ACTH
- Adrenocorticotropic hormone, the pituitary signal that stimulates adrenal cortisol production.
- Postoperative ileus
- Delayed restoration of coordinated bowel movement after surgery.
- Terminal half-life
- Time for plasma concentration to fall by half during the modeled final elimination phase.
- Cholinergic
- Using acetylcholine as a nerve signal.